New drug cocktail shows promise against rare blood cancer
NCT ID NCT04273139
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two targeted drugs, ibrutinib and venetoclax, in 45 adults with a rare blood cancer called Waldenström macroglobulinemia who have a specific gene mutation (MYD88). The goal is to see if the combo can shrink the cancer significantly. Participants take both pills by mouth, and the study tracks how many achieve a very good partial response within about two years.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYD88 GENE MUTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02214, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Smartwatches track hidden heart risk in blood cancer patients
- Can a tailored exercise and diet plan beat cancer fatigue?
- Immunotherapy combo shows promise for Tough-to-Treat blood cancers
- New drug duo shows promise for rare blood cancer
- New hope for rare blood cancer: targeted drug shows promise in early trial
- Gut bacteria drug shows promise against blood disorder